Good closing volume with a block buy at 50k shares at 3:59. Again, that one trade is ~165k which is generally beyond most retailers. I think given the potential upside catalysts we'll see a continuation of today's run with bigger volume.
I think the news of today's PR is just getting out. One guy I talked to started a 100k personal position and will add professionally when able.
The future looks great both short and long term.
Can someone remind me why we are going into Phase II for B-OM and not Phase I....I know I should know this but for some reason it completely escapes me....although I am very happy about it, I cannot for the life of me remember why.
I can only imagine what you pocketed on this little unexpected CTIX PR run....
Stay stateside and throw that party, actually oysters are better during the winter harvest, so we fellow shareholders can wait till after that San Fran trip.
Not worth it IMHO. Stay cavalier, do a B deal to kick off with a top 5, and don't panic, all is good in the ctix hood. Science will trump all and create the value not impatience.
Yea the "aww shucks" was getting real old,.
GLTA CTIXers
Over the next six weeks we have:
Start of the B-OM trial at MD Anderson
Start of K in AML at UofB
Bottom line B 2b results with FDA comments which could be huge!!
Prurisol FDA meeting
And just because of the last PR perhaps even more information on Kevetrin solid tumors p1????
Uplisting???
Anything else? Not sure what the share price will be but the entertainment value is going off the charts for me.
For the Bakers, private placement sell of 10-20 million shares at current market prices of course and a seat on the board.
I did at $3.32. With reservations of course.
Close at the high is worrisome but volume wasn't striking. Suspect next big push related to B results.
Won't wait long to reload if funds available.
Baker Bros! I would think we are on the verge of one of these entities endorsing CTIX.
I imagine you saw what I saw today. Demand at the upper ranges of today's trade range ($3.30+). Smart money? Not sure myself. But, could be some fresh money is coming into play.
Looking at the trade, I think it likely that the PPS goes back to test recent highs. There should be (natural) resistance at this level. Still 5%+ to go before.
Not sure if most have observed what I have. Weakness has been more a product of weak demand (buying), not over supply (selling). This phenomena (weak demand) was one of the clues I used in determining that CTIX was ready for some consolidation, last week. Probably not a coincidence that CTIX was in overbought territory, that it had tested the high range and failed several times, and that volume was getting lighter (just before the minor correction/consolidation).
Volume means different things at different times. For instance, the drying up of volume at the end of a consolidation is a good thing (sellers are near finished). But, volume drying up at the end of a strong move higher is most likely bad news, as demand is slacking off. Big increases in volume (40% plus) can signal turnarounds. Just as candlesticks need to be interpreted in the context of dynamic trading, so too volume.
Liked the volume today. Like that stochastics are low. Like that CTIX is trading within Bollinger bands. Waiting to see how CTIX reacts when hitting resistance and in overbought territory. It's coming. Not today. The market will tell. Then, breakout or consolidation. Consolidation or correction.
Hope you noticed that during the long run from $1.60, I was not taken in by many of the short-term, head fake consolidations.
One also needs to put recent PPS activities in context. CTIX has a much higher market value than just a few months ago). Compared with today, trading a few months ago was much less risky (in price terms). Also, CTIX has been advancing its technologies, which has reduced risk. Then there is the shelf offering, and new COO (with compensations). Pluses and minuses, and will depend on one's perspective. My perspective, it's more positive.
Happy trails, I mean trading:
remember when jb and greyhound went to the feb conference? jb quoted dr menon as saying (in regards to p53 & p21) that dana farber wanted to see the graphs (dosage & expression) go up at the same time.
from todays pr
preliminary data show that 50 percent of patients treated with kevetrin hrough the eighth cohort demonstrated enhancement in p21 expression in peripheral blood cells and that these observations appeared dose related
......Initial comparisons between early and latter cohorts
support cellceutix's expectation that p53 is dependent on exposure to kevetrin.
in other words the amount of increase of p21 is dependent on the amount of kevetrin injected. the graphs correlate.
now the last thing we need to hear is how this affects the tumors.
You may be thinking of Baker Bros.
Sabby and 3 or 4 others are also really big in biotech/pharmas.
volume is AWESOME today! close at EOD high!
Weekly is almost bullish engulfing!
Nice move today for CTIX...
was 900k shares good volume for this day?
Now it needs to hold support above the 3.00-3.15 area to stay looking good. (technically speaking of course...)
Even a well known science/medical magazine feature would be a nice start. I forget who the group is that is real influential in biotech investments, but surprised we haven't seen them enter the picture. Maybe they are accumulating currently.
Yep, don't want to be out when something like this hits, and an RSI of 95 won't stop a huge gain from that type of exposure.
HOLY SHITOWSKI and I ain't POLISH !
I LOVE LEO & the CTIX LEADERSHIP GANG !
GOOOOOOOOOOOOOOOOO CTIX !
We should start a pool for which network will pick up the CTIX story first...
Yes today was awesome!
You know, today really was enjoyable. And I'm tempted to make a special trip just to see the display at the tower of London...that may well be the best signature you've ever posted.
Securities Registration Statement (simplified Form) (s-3/a) "Edgar (US Regulatory)" - 11/10/2014 5:31:51 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/10/2014 4:16:35 PM
Hot Stocks to Follow for Investment Opportunity & Special Profile "InvestorsHub NewsWire" - 11/6/2014 6:00:00 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 10/30/2014 4:31:15 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/24/2014 6:04:28 AM
ALTITRADE PARTNERS™ SAYS A KEY-REVERSAL DAY COULD HAPPEN THIS WEEK "InvestorsHub NewsWire" - 10/14/2014 6:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/24/2014 3:48:22 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/15/2014 1:50:04 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 9/4/2014 4:14:23 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/2/2014 6:29:26 AM
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant "Marketwired" - 6/23/2014 7:00:00 AM
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort "Marketwired" - 6/16/2014 7:00:00 AM
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol "Marketwired" - 6/2/2014 7:00:00 AM
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities "Marketwired" - 5/27/2014 7:00:00 AM
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market "Marketwired" - 5/19/2014 7:00:00 AM
Amended Quarterly Report (10-q/a) "Edgar (US Regulatory)" - 5/16/2014 11:57:54 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/12/2014 10:12:29 AM
Cellceutix Confident in Its Formidable Antibiotic Arsenal "Marketwired" - 5/12/2014 7:00:00 AM
Cohort Completed in Cellceutix Clinical Trial of Prurisol for Psoriasis "Marketwired" - 5/5/2014 9:53:20 AM
Study Shows Cellceutix Antibiotic Active Against Drug-Resistant Superbug Klebsiella Pneumoniae "Marketwired" - 4/14/2014 6:30:00 AM
Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid "Marketwired" - 4/1/2014 8:00:00 AM
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI "Marketwired" - 3/31/2014 9:25:00 AM
Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis "Marketwired" - 3/25/2014 6:00:00 AM
Cellceutix to Initiate Psoriasis Clinical Trial "Marketwired" - 3/21/2014 6:00:00 AM
Seventh Cohort Underway in Cellceutix Clinical Trial of Kevetrin for Solid Tumors "Marketwired" - 3/19/2014 8:40:37 AM